Lung Function After Stereotactic Body Radiation Therapy for Early-Stage Non-Small Cell Lung Cancer, Changes and Predictive Markers

被引:17
作者
Berg, Janna [1 ,2 ]
Ramberg, Christina [3 ]
Haugstvedt, Jon Olav Sulheim [4 ]
Bengtson, May-Bente [1 ]
Gabrielsen, Anne-Marie [1 ]
Brustugun, Odd Terje [2 ,5 ]
Halvorsen, Ann Rita [6 ,7 ]
Helland, Aslaug [2 ,6 ,7 ]
机构
[1] Vestfold Hosp Trust, Dept Med, Tonsberg, Norway
[2] Oslo Univ Hosp, Norwegian Radium Hosp, Inst Canc Res, Dept Canc Genet, Oslo, Norway
[3] Oslo Univ Hosp, Dept Med Phys, Oslo, Norway
[4] Vestfold Hosp Trust, Dept Radiol & Nucl Med, Tonsberg, Norway
[5] Vestre Viken Hosp Trust, Sect Oncol, Drammen, Norway
[6] Oslo Univ Hosp, Dept Oncol, Oslo, Norway
[7] Univ Oslo, Dept Clin Med, Oslo, Norway
来源
FRONTIERS IN ONCOLOGY | 2021年 / 11卷
关键词
non-small cell lung cancer (NSCLC); stereotactic body radiation therapy (SBRT); radiation pneumonitis; pulmonary function test; radiotherapy dose-volume; toxicity; LINE PULMONARY-FUNCTION; ABLATIVE RADIOTHERAPY; DIFFUSING-CAPACITY; PNEUMONITIS; TOXICITY; SBRT; DECLINE; TIME; APPEARANCE; CRITERIA;
D O I
10.3389/fonc.2021.674731
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Introduction The present study explores changes in pulmonary function, symptoms and radiological signs of pneumonitis after curatively intended stereotactic body radiation therapy (SBRT). Methods All inoperable, early-stage non-small cell lung cancer patients treated with stereotactic body radiation therapy (SBRT) from 2014-2017 were included in this single-centre study. They were followed regularly for 12 months after treatment. The patients were classified into three groups based on radiology and symptomatology: no radiation pneumonitis, asymptomatic and symptomatic radiation pneumonitis. Results Forty-four patients with stage IA-IIB disease were treated with 45-56 Gy in 3-8 fractions. The median age was 75 years, 43% of the patients were female; 60% of the patients had a COPD in GOLD grade of 2-4, and 95.5% were active or former smokers. Symptomatic radiation pneumonitis occurred in 18% of the patients and asymptomatic pneumonitis as defined by radiology, in 39%. The mean of forced expiratory volume in 1 second (FEV1) and diffusion capacity for carbon monoxide (DLCO) decreases for all patients during the first years were higher than one would expect from physiologic ageing. FEV1 and DLCO in percent decrease 7-8% at 1-1.5 months in the symptomatic radiation pneumonitis group. CT scan findings consistent with radiation pneumonitis occurred after a median of 2.9 months in the symptomatic and 5.4 months in the asymptomatic radiation pneumonitis groups. In the group with symptomatic radiation pneumonitis, symptoms, as measured by the Clinical COPD questionnaire score, significantly increased at 3 and 6 months. Significant higher maximum doses to the critical lung volumes DC1000cm(3) (1000 cm(3) of lung receiving a given dose or less) and DC 1500cm(3) (1500 cm(3) of lung receiving a given dose or less) were observed in patients who developed radiation pneumonitis. Conclusion Early decrease in measured FEV1 and DLCO occurred before imaging changes and symptoms and might indicate the development of symptomatic radiation pneumonitis. The dose to critical lung volumes of DC1000 cm(3) and DC1500 cm(3) may predict the risk for the development of symptomatic radiation pneumonitis.
引用
收藏
页数:11
相关论文
共 42 条
  • [1] Evaluation of lung injury after three dimensional conformal stereotactic radiation therapy for solitary lung tumors: CT appearance
    Aoki, T
    Nagata, Y
    Negoro, Y
    Takayama, K
    Mizowaki, T
    Kokubo, M
    Oya, N
    Mitsumori, M
    Hiraoka, M
    [J]. RADIOLOGY, 2004, 230 (01) : 101 - 108
  • [2] Stereotactic body radiotherapy for medically inoperable patients with stage I non-small cell lung cancer - A first report of toxicity related to COPD/CVD in a non-randomized prospective phase II study
    Baumann, Pia
    Nyman, Jan
    Hoyer, Morten
    Gagliardi, Giovanna
    Lax, Ingmar
    Wennberg, Berit
    Drugge, Ninni
    Ekberg, Lars
    Friesland, Signe
    Johansson, Karl-Axel
    Lund, Jo-Asmund
    Morhed, Elisabeth
    Nilsson, Kristina
    Levin, Nina
    Paludan, Merete
    Sederholm, Christer
    Traberg, Anders
    Wittgren, Lena
    Lewensohn, Rolf
    [J]. RADIOTHERAPY AND ONCOLOGY, 2008, 88 (03) : 359 - 367
  • [3] Stereotactic body radiation therapy: The report of AAPM Task Group 101
    Benedict, Stanley H.
    Yenice, Kamil M.
    Followill, David
    Galvin, James M.
    Hinson, William
    Kavanagh, Brian
    Keall, Paul
    Lovelock, Michael
    Meeks, Sanford
    Papiez, Lech
    Purdie, Thomas
    Sadagopan, Ramaswamy
    Schell, Michael C.
    Salter, Bill
    Schlesinger, David J.
    Shiu, Almon S.
    Solberg, Timothy
    Song, Danny Y.
    Stieber, Volker
    Timmerman, Robert
    Tome, Wolfgang A.
    Verellen, Dirk
    Wang, Lu
    Yin, Fang-Fang
    [J]. MEDICAL PHYSICS, 2010, 37 (08) : 4078 - 4101
  • [4] BJERMER L, 1993, EUR RESPIR J, V6, P1173
  • [5] Coming together: the ATS/ERS consensus on clinical pulmonary function testing
    Brusasco, V
    Crapo, R
    Viegi, G
    [J]. EUROPEAN RESPIRATORY JOURNAL, 2005, 26 (01) : 1 - 2
  • [6] TOXICITY CRITERIA OF THE RADIATION-THERAPY ONCOLOGY GROUP (RTOG) AND THE EUROPEAN-ORGANIZATION-FOR-RESEARCH-AND-TREATMENT-OF-CANCER (EORTC)
    COX, JD
    STETZ, J
    PAJAK, TF
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1995, 31 (05): : 1341 - 1346
  • [7] Pulmonary function and quality of life after VMAT-based stereotactic ablative radiotherapy for early stage inoperable NSCLC: a prospective study
    Ferrero, Cinzia
    Badellino, Serena
    Filippi, Andrea Riccardo
    Focaraccio, Luana
    Levra, Matteo Giaj
    Levis, Mario
    Moretto, Francesco
    Torchio, Roberto
    Ricardi, Umberto
    Novello, Silvia
    [J]. LUNG CANCER, 2015, 89 (03) : 350 - 356
  • [8] SOUTHWEST-ONCOLOGY-GROUP STANDARD RESPONSE CRITERIA, END-POINT DEFINITIONS AND TOXICITY CRITERIA
    GREEN, S
    WEISS, GR
    [J]. INVESTIGATIONAL NEW DRUGS, 1992, 10 (04) : 239 - 253
  • [9] Dose-response relationship for radiation-induced pneumonitis after pulmonary stereotactic body radiotherapy
    Guckenberger, Matthias
    Baier, Kurt
    Polat, Buelent
    Richter, Anne
    Krieger, Thomas
    Wilbert, Juergen
    Mueller, Gerd
    Flentje, Michael
    [J]. RADIOTHERAPY AND ONCOLOGY, 2010, 97 (01) : 65 - 70
  • [10] Risk of Pneumonitis After Stereotactic Body Radiation Therapy in Patients With Previous Anatomic Lung Resection
    Hayes, Jason T.
    David, Elizabeth A.
    Qi, LiHong
    Chen, Allen M.
    Daly, Megan E.
    [J]. CLINICAL LUNG CANCER, 2015, 16 (05) : 379 - 384